Azathioprine therapy inhibits development of new lesions in multiple sclerosis patients
Kate Matthews
This article has no abstract so we have provided the first paragraph of the full text.
Treatment with azathioprine, an immunosuppressive drug, reduces the rate of relapse in patients with multiple sclerosis (MS); however, it is unknown whether this therapy also inhibits the development of new lesions. Massacesi et al. used MRI to investigate whether azathioprine therapy suppresses the number and accumulation of new brain lesions in patients with MS.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Multiple sclerosis: TNF revisited, with promiseNature Medicine News and Views (01 Mar 1995)